H.C. Wainwright Downgrades Rapt Therapeutics (RAPT) to Neutral

Rapt Therapeutics (RAPT) PT Lowered to $32 at Wells Fargo

Wells Fargo analyst Yanan Zhu lowered the price target on Rapt Therapeutics (NASDAQ: RAPT) to $32.00 (from $42.00) while maintaining a Overweight rating.... More

Rapt Therapeutics (RAPT) PT Lowered to $13 at Barclays

Barclays analyst Leon Wang lowered the price target on Rapt Therapeutics (NASDAQ: RAPT) to $13.00 (from $35.00) while maintaining a Overweight rating.... More

JPMorgan Downgrades Rapt Therapeutics (RAPT) to Neutral 'on Zelnecirnon Clinical Hold Unknowns'

(Updated - February 21, 2024 4:02 AM EST)

JPMorgan analyst Anupam Rama downgraded Rapt Therapeutics (NASDAQ: RAPT) from Overweight to Neutral with a price target of $15.00 (from $35.00).

The analyst comments "We are moving to a Neutral rating (prior Overweight rating) and December 2024 PT of $15 (prior $35) on todays announcement that lead asset zelnecirnon (RPT193) has been placed on clinical hold by the FDA. The clinical hold for zelnecirnon was driven by a single severe adverse event of liver failure in the phase 2b study... More

Cantor Fitzgerald Downgrades Rapt Therapeutics (RAPT) to Neutral, 'Too Many Unknowns Right Now'

Cantor Fitzgerald analyst Prakhar Agrawal downgraded Rapt Therapeutics (NASDAQ: RAPT) from Overweight to Neutral.

The analyst commented: "RAPT announced that the FDA has verbally notified the company that a clinical hold (full) has been placed on the ongoing trials for lead inflammation drug called... More

RAPT Therapeutics (RAPT) Announces Clinical Hold on Studies Evaluating Zelnecirnon

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the companys Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma. The company expects to receive a formal clinical hold letter from the FDA. The clinical hold... More

RAPT Therapeutics (RAPT) Halted, News Pending

RAPT Therapeutics (NASDAQ: RAPT) Halted, News Pending